These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 37095712)

  • 21. Five-year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort.
    Chen S; Huang Z; Liang Y; Zhao X; Aobuliksimu X; Wang B; He Y; Kang Y; Huang H; Li Q; Yao Y; Lu X; Qian X; Xie X; Liu J; Liu Y
    ESC Heart Fail; 2022 Aug; 9(4):2336-2347. PubMed ID: 35437939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
    Mazza A; Townsend DM; Torin G; Schiavon L; Camerotto A; Rigatelli G; Cuppini S; Minuz P; Rubello D
    Biomed Pharmacother; 2020 Oct; 130():110596. PubMed ID: 34321170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
    Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study.
    Jang J; Park S; Kim S; Kim SH; Oh YS; Sa YK; Hwang Y; Jang SW; Ihm SH; Choi Y
    Eur J Prev Cardiol; 2024 Feb; 31(3):320-329. PubMed ID: 37798123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry.
    Stolfo D; Lund LH; Benson L; Lindberg F; Ferrannini G; Dahlström U; Sinagra G; Rosano GMC; Savarese G
    Eur J Heart Fail; 2023 Sep; 25(9):1648-1658. PubMed ID: 37419495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics and outcomes for patients with heart failure diagnosed according to the universal definition and classification of heart failure. Data from a single-center registry.
    Niedziela JT; Rozentryt P; Nowak J; Szyguła-Jurkiewicz B; Pyka Ł; Cieśla D; Gąsior M
    Kardiol Pol; 2024; 82(4):391-397. PubMed ID: 38493451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registry.
    Becher PM; Savarese G; Benson L; Dahlström U; Karlström P; Mol PGM; Metra M; Bhatt DL; Pitt B; Lund LH
    Eur Heart J Cardiovasc Pharmacother; 2023 Jun; 9(4):343-352. PubMed ID: 36718512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of left ventricular ejection fraction phenotypes on healthcare resource utilization in hospitalized heart failure: a secondary analysis of REPORT-HF.
    Farmakis D; Tromp J; Marinaki S; Ouwerkerk W; Angermann CE; Bistola V; Dahlstrom U; Dickstein K; Ertl G; Ghadanfar M; Hassanein M; Obergfell A; Perrone SV; Polyzogopoulou E; Schweizer A; Boletis I; Cleland JGF; Collins SP; Lam CSP; Filippatos G
    Eur J Heart Fail; 2023 Jun; 25(6):818-828. PubMed ID: 36974770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain).
    Farré N; Lupon J; Roig E; Gonzalez-Costello J; Vila J; Perez S; de Antonio M; Solé-González E; Sánchez-Enrique C; Moliner P; Ruiz S; Enjuanes C; Mirabet S; Bayés-Genís A; Comin-Colet J;
    BMJ Open; 2017 Dec; 7(12):e018719. PubMed ID: 29273666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mild and moderate to severe early acute kidney injury following cardiac surgery among patients with heart failure and preserved vs. mid-range vs. reduced ejection fraction: A retrospective cohort study.
    Gao Y; Wang C; Li J; Ji B; Wang J; Yan F; Wang Y
    Eur J Anaesthesiol; 2022 Aug; 39(8):673-684. PubMed ID: 35791895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of Chronic Heart Failure in Advanced Chronic Kidney Disease: The HAKA Multicenter Retrospective Real-World Study.
    Quiroga B; Ortiz A; Núñez S; Kislikova M; González Sanchidrián S; Broseta JJ; Albines ZS; Escamilla Cabrera B; Rivero Viera Y; Rodriguez Santarelli D; Salanova Villanueva L; Lopez Rodriguez F; Cancho Castellano B; Ibáñez Cerezon M; Gutierrez Rivas CP; Aresté N; Campos Gutiérrez B; Ródenas Gálvez A; Glucksmann Pizá MC; Balda Manzanos S; Soldevila A; Rodríguez Gayo L; Moral Berrio E; Ortega Diaz M; Beltrán Catalán S; Puente García A; Ángel Rojas M; Sosa Barrios RH; Santana Zapatero H; Rangel Hidalgo G; Martinez Canet AM; Díez J;
    Cardiorenal Med; 2024; 14(1):202-214. PubMed ID: 38513622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical characteristics and prognosis of heart failure with mid-range ejection fraction: insights from a multi-centre registry study in China.
    Lyu S; Yu L; Tan H; Liu S; Liu X; Guo X; Zhu J
    BMC Cardiovasc Disord; 2019 Sep; 19(1):209. PubMed ID: 31477021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: A pre-specified analysis of the DELIVER trial.
    Lassen MCH; Ostrominski JW; Inzucchi SE; Claggett BL; Kulac I; Jhund P; de Boer RA; Hernandez AF; Kosiborod MN; Lam CSP; Martinez FA; Shah SJ; Desai AS; Petersson M; Langkilde AM; Docherty KF; McMurray JJV; Solomon SD; Vaduganathan M
    Eur J Heart Fail; 2024 Jul; 26(7):1539-1548. PubMed ID: 38745498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 20 Years of Real-World Data to Estimate the Prevalence of Heart Failure and Its Subtypes in an Unselected Population of Integrated Care Units.
    Gavina C; Carvalho DS; Valente F; Bernardo F; Dinis-Oliveira RJ; Santos-Araújo C; Taveira-Gomes T
    J Cardiovasc Dev Dis; 2022 May; 9(5):. PubMed ID: 35621860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Considerations for Use of SGLT2 Inhibitor Therapy in Patients with Heart Failure and Reduced Ejection Fraction: A Review.
    Jhalani NB
    Adv Ther; 2022 Aug; 39(8):3472-3487. PubMed ID: 35699903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
    Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
    Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure.
    McMurray JJV; Wheeler DC; Stefánsson BV; Jongs N; Postmus D; Correa-Rotter R; Chertow GM; Hou FF; Rossing P; Sjöström CD; Solomon SD; Toto RD; Langkilde AM; Heerspink HJL;
    JACC Heart Fail; 2021 Nov; 9(11):807-820. PubMed ID: 34446370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world eligibility for vericiguat in decompensated heart failure with reduced ejection fraction.
    Oh J; Lee CJ; Park JJ; Lee SE; Kim MS; Cho HJ; Choi JO; Lee HY; Hwang KK; Kim KH; Yoo BS; Choi DJ; Baek SH; Jeon ES; Kim JJ; Cho MC; Chae SC; Oh BH; Kang SM
    ESC Heart Fail; 2022 Apr; 9(2):1492-1495. PubMed ID: 35142095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
    Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
    Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.